Request for Support in Dissertation Research on Genetic Competencies for Pharmacist working in cancer

Dear Members,

The BOPA research committee would like to invite members to participate in a research project on Genetic core competencies for clinical pharmacists in the cancer setting: a literature review and Delphi method. Below is the letter of invitation:

“My name is Delia D’Agostino, and I am a Senior Rotational Pharmacist at The Royal Marsden NHS Foundation Trust, London. I am currently undertaking a master’s degree in clinical oncology and would greatly appreciate your support in my dissertation research.

This study aims to define a core curriculum of genetic competencies essential for clinical pharmacists working in oncology. Additionally, it seeks to explore practical approaches for delivering genetic education to the pharmacy workforce.

The project consists of a literature review to identify relevant genetic competencies, followed by the development of a Delphi methodology-based questionnaire. I seek the support of BOPA members in completing this questionnaire to achieve a consensus on the competencies and their optimal educational delivery.

The process will proceed as follows:
1. If interested in participating in the questionnaire, BOPA members receiving this email are asked to come forward by replying by 16/05/25. Note that the inclusion criteria are Band 7 pharmacists and above with at least two years of cancer experience.
2. The first questionnaire will be distributed on 30/05/2025 to those who had expressed interest via a dedicated online platform, with a link included in the invitation email.
3. The questionnaire will undergo two further rounds in June and July 2025 respectively, incorporating responses from previous rounds. Participants will provide consent for the anonymous use of their answers. Ethical approval is not required as no confidential data will be collected. The timeline for each round will be the following:

  • Round 1 completion by 13/06/2025
  • Round 2 completion by 27/06/2025
  • Round 3 completion by 11/07/2025

Each round of the questionnaire will take around 1 hour to complete

4. Data analysis and results presentation will follow and be completed by October 2025.
Please find attached the project protocol for further details.

If you fit the inclusion criteria as above (point 1), and you are interested in participating in the project, I kindly request your response by 16/05/25. To do so, please send an expression of interest to [email protected] stating your email address. Please note that this is the same address you will be contacted on upon starting of each questionnaire round and where you will receive any other relevant information about the project.

Should you have any questions, please do not hesitate to contact me.”

Kind regards,

BOPA research committee

on behalf of Delia D’Agostino.

 

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article